Biodefense Breaking News: Ebola Patient Who Received
Aethlon (OTCBB: AEMD) Hemopurifier® Therapy Has Been Discharged From Hospital
SAN DIEGO - November 25, 2014 (Investorideas.com newswire)
Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic
devices to address infectious disease and cancer, disclosed today that an Ebola
patient who received Hemopurifier® therapy has been reported to have been
discharged from Frankfurt University Hospital in Germany. The patient was a
Ugandan physician, who became infected with Ebola in Sierra Leone where he was
treating other Ebola patients.
The
Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets
the rapid elimination of viruses and immunosuppressive proteins from the
circulatory system of infected individuals. At the time Hemopurifier® therapy
was administered to the Ugandan physician, he was unconscious and suffered from
multiple organ failure. His viral load prior to the administration of a single
6.5-hour Hemopurifier® treatment was measured at 400,000 virus copies per
milliliter of blood (copies/ml). Post-treatment viral load was measured at
1,000 copies/ml and never again rose above that level. Viral load became
undetectable five days after therapy. The treatment was well tolerated with no
adverse events reported. Additionally, a post-treatment elution protocol
verified that 242 million Ebola viruses were captured within the Hemopurifier®
during treatment.
In the United States, Hemopurifier® therapy
is available to treat Ebola patients through FDA expanded access
"emergency use" provisions to address life threatening circumstances
for which an alternative therapy is not available. At present, no antiviral
therapy or vaccine has proven to be effective against Ebola virus infection in
humans.
Aethlon will soon begin the first U.S.
clinical Hemopurifier® studies following the United States Food and Drug
Administration's (FDA)'s approval of an Investigational Device Exemption (IDE).
The study will contribute safety data to advance the device as a broad-spectrum
countermeasure against bioterror and pandemic threats, including Ebola and
chronic viral pathogens such as HIV and Hepatitis C (HCV).
Read this release
in full at http://www.investorideas.com/CO/AEMD/news/2014/11251.asp
About Aethlon Medical, Inc.
Aethlon
Medical creates targeted therapeutic devices to address infectious disease,
cancer and neurodegenerative disorders. The company's lead product is the
Aethlon Hemopurifier®, a first-in-class antiviral and immunotherapeutic device
that selectively targets the broad-spectrum elimination of circulating viruses
and tumor-secreted exosomes that promote cancer progression. Exosome Sciences,
Inc. is a majority owned subsidiary that is advancing exosome-based products to
diagnose and monitor cancer, infectious disease and neurological disorders. For
more information, please visit http://www.aethlonmedical.com and connect with
the Company on Twitter, LinkedIn,
Facebook and Google+.
Certain statements herein may be forward-looking and involve
risks and uncertainties. Such forward-looking statements involve assumptions,
known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of Aethlon Medical, Inc. to be
materially different from any future results, performance, or achievements
expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, that the ESI will not be able to
commercialize its future products, that the FDA will not approve the initiation
of the Company's clinical programs or provide market clearance of the company's
products, future human studies whether revenue or non-revenue generating of the
Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to
improve patient responsiveness to established cancer or hepatitis C therapies
or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense
against viral pathogens, including ebola, the Company's ability to raise
capital when needed, the Company's ability to complete the development of its
planned products, the Company's ability to manufacture its products either
internally or through outside companies and provide its services, the impact of
government regulations, patent protection on the Company's proprietary
technology, the ability of the Company to meet the milestones contemplated in
the DARPA contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of factors,
including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party
publisher of news and research as well as creates original content as a news
source. Original content created by investorideas is protected by copyright
laws other than syndication rights. Investorideas is a news source on Google
news and Linkedintoday plus hundreds of syndication partners. Our site does not
make recommendations for purchases or sale of stocks or products. Nothing on
our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated by featured companies, news
submissions, content marketing and online advertising. Contact each company
directly for press release questions. Disclosure is posted on each release if
required but otherwise the news was not compensated for and is published for
the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock
directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and
more...
